BOSTON - Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian, government and military use, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has initiated funding to support the onshoring of Paratek manufacturing activities for NUZYRA.

The reimbursement cost for the onshoring and security requirement activities is projected to total approximately $20 million.

In December 2019, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, awarded Paratek a five-year contract, valued at up to $285 million, to support: 1) the development of NUZYRA for the treatment of pulmonary anthrax; 2) all of the U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; 3) U.S. onshoring and manufacturing security requirements and 4) the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax.

'We are committed to studying NUZYRA in the fight against antimicrobial resistance and the treatment and prophylaxis of anthrax and believe that NUZYRA will play an important role in supporting the biodefense preparedness of our country,' said Evan Loh, MD, CEO, Paratek. 'Establishing our entire manufacturing process in the United States and ensuring that these facilities are secure is an important step for protecting Americans and for pandemic preparedness. This initiative helps to further secure NUZYRA's overall supply chain, adding a comprehensive secondary supply chain to our existing infrastructure, and over the projected collaboration timeframe, will provide for a secure, United States based manufacturing supply chain. We look forward to working with BARDA to meet all of these goals.'

Under the terms of the contract that has now been initiated, Paratek will commit to ensure that all current suppliers meet BARDA security requirements and to onshore a secondary supply chain in the United States for NUZYRA.

About NUZYRA

NUZYRA (omadacycline) is a novel antibiotic with both once-daily oral and intravenous (IV) formulations for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, atypicals, and other drug-resistant strains.

About Paratek Pharmaceuticals, Inc.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The company's lead commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC, or Almirall. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of NUZYRA for the treatment of pulmonary anthrax.

Forward Looking Statements

This press release contains forward-looking statements including statements related to our overall strategy, products, prospects, potential success for treating anthrax, timing and value of the BARDA award and contract, strength of our supply chain and potential of the business. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as 'advancing,' 'expect,' 'look forward,' 'anticipate,' 'continue,' and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements. Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties. These and other risk factors are discussed under 'Risk Factors' and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2018 and our other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

Contact:

Ben Strain

Tel: 617-807-6688

Email: ir@ParatekPharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire